Korean Pharma Q3 Roundup: Mixed Earnings, Taxotere Deal, R&D Advances

 
• By Jung Won Shin
  
third quarter review
Daewoong, SK Biopharm Among Solid Q3 Performers (Shutterstock)

More from Earnings

More from Business